{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.51","upperLimit":"0.82","value":"0.70"},{"groupId":"OG001","lowerLimit":"0.10","upperLimit":"0.58","value":"0.37"},{"groupId":"OG002","lowerLimit":"-0.16","upperLimit":"0.39","value":"0.12"},{"groupId":"OG003","lowerLimit":"-0.07","upperLimit":"0.47","value":"0.22"},{"groupId":"OG004","lowerLimit":"-0.37","upperLimit":"0.19","value":"-0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"54"},{"groupId":"OG004","value":"51"}],"units":"Participants"}],"title":"Baseline P1NP (Spearman's Rank Correlation Coefficient)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-0.04","upperLimit":"0.50","value":"0.25"},{"groupId":"OG002","lowerLimit":"-0.28","upperLimit":"0.29","value":"0.00"},{"groupId":"OG003","lowerLimit":"0.03","upperLimit":"0.55","value":"0.32"},{"groupId":"OG004","lowerLimit":"-0.47","upperLimit":"0.09","value":"-0.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"54"},{"groupId":"OG004","value":"51"}],"units":"Participants"}],"title":"Baseline CTX-1 (Spearman's Rank Correlation Coefficient)"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"-0.19","upperLimit":"0.36","value":"0.09"},{"groupId":"OG003","lowerLimit":"-0.31","upperLimit":"0.24","value":"-0.04"},{"groupId":"OG004","lowerLimit":"-0.48","upperLimit":"0.06","value":"-0.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"54"},{"groupId":"OG004","value":"51"}],"units":"Participants"}],"title":"Baseline ALP (Spearman's Rank Correlation Coefficient)"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-0.16","upperLimit":"0.37","value":"0.11"},{"groupId":"OG004","lowerLimit":"-0.15","upperLimit":"0.39","value":"0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"54"},{"groupId":"OG004","value":"51"}],"units":"Participants"}],"title":"Baseline DKK1 (Spearman's Rank Correlation Coefficient)"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"-0.53","upperLimit":"-0.01","value":"-0.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"51"}],"units":"Participants"}],"title":"Baseline Sclerostin (Spearman's Rank Correlation Coefficient)"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Baseline RANKL:OPG (Spearman's Rank Correlation Coefficient)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"54"},{"groupId":"OG004","value":"51"}],"units":"Participants"}],"description":"Primary Outcome 2: To assess whether the novel magnetic resonance (MR) protocol and exploratory bone turnover markers can improve quantification of bone loss in patients with myeloma (new, relapsed, smouldering) and Monoclonal Gammopathy Of Uncertain Significance (MGUS) at baseline assessment, compared to Dual-energy X-ray Absorptiometry (DXA) and established bone turnover markers alone.\n\nIn this particular section, Spearman's rank correlation coefficient was performed to assess correlations between all pairs of bone turnover markers, measured at baseline in a pooled cohort of participants from Groups 1 and 2:\n\n1. P1NP (Procollagen Type 1 N-terminal Propeptide);\n2. CTX-1 (Collagen Cross-Linked C-Telopeptide Type I);\n3. ALP (Alkaline Phosphatase);\n4. DKK1 (Dickkopf WNT Signaling Pathway Inhibitor 1);\n5. Sclerostin;\n6. Ratio of RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand) to OPG (Osteoprotegerin).","dispersionType":"95% Confidence Interval","groups":[{"description":"Baseline measurements of CTX-1 (Type I Collagen Cross-Linked C-Telopeptide).","id":"OG000","title":"Baseline CTX-1"},{"description":"Baseline measurements of ALP (Alkaline Phosphatase).","id":"OG001","title":"Baseline ALP"},{"description":"Baseline measurements of DKK1 (Dickkopf WNT Signaling Pathway Inhibitor 1).","id":"OG002","title":"Baseline DKK1"},{"description":"Baseline measurements of sclerostin.","id":"OG003","title":"Baseline Sclerostin"},{"description":"Baseline measurements of the ratio between RANKL and OPG (osteoprotegerin).","id":"OG004","title":"Baseline RANKL:OPG"}],"paramType":"NUMBER","populationDescription":"Pooled population of participants from Groups 1 and 2 who had bone biomarkers measured at baseline.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Primary Outcome 2: Quantifying Bone Loss (Inter-Biomarker Correlations)","type":"PRIMARY","unitOfMeasure":"Spearman's rank correlation coefficient"}